Neurocrine Biosciences Inc (NBIX)

Trade NBIX now with
11/4/2019 4:03:08 PM Neurocrine Biosciences Q3 EPS $0.56 Vs. $0.52 Year Ago
9/30/2019 4:02:01 PM Neurocrine Biosciences Appoints David Boyer As Chief Corporate Affairs Officer
9/11/2019 4:02:43 PM Neurocrine Biosciences Appoints Leslie Norwalk To Board Of Directors
8/5/2019 8:32:20 AM AbbVie Submits NDA For Elagolix For Management Of Heavy Menstrual Bleeding Associated With Uterine Fibroids In Women
7/29/2019 4:05:07 PM Neurocrine Biosciences Q2 EPS $0.54 Vs. Loss $0.07 Year Ago
5/20/2019 8:05:34 AM Neurocrine Biosciences Presents New Data From RE-KINECT
5/5/2019 10:30:23 AM Neurocrine And Voyager Therapeutics Announce Phase I Results For VY-AADC In Patients With Parkinson's Disease
5/5/2019 10:29:55 AM Neurocrine Announces Presentation Of Data Analysis From Two Phase III Studies Of Opicapone
4/29/2019 4:04:38 PM Neurocrine Biosciences Q1 Loss/share $1.12 Vs. Loss $0.47 Year Ago
3/12/2019 8:02:52 AM Neurocrine Reports Interim Results From PhaseII Study Of NBI-74788 In Adults With Classic Congenital Adrenal Hyperplasia